IFNA1 and systemic lupus erythematosus: Treatment with anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 was associated with decreased IFN signature in adult-onset SLE and clinical benefit in a phase 3 RCT [232], despite initially not meeting the primary endpoint, SLE responder index 4 (SRI4) [233].